A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Research Site, Bruges

Research Site, New York

Research Site, Lake Success

Research Site, Washington D.C.

Research Site, Madrid

Research Site, Haifa

Research Site, Nashville

Research Site, Columbus

Research Site, Milwaukee

Research Site, Chicago

Research Site, Houston

Research Site, Tucson

Research Site, La Jolla

Research Site, Palo Alto

Research Site, Concord

Research Site, Seattle

Research Site, Seattle

Research Site, Spokane

Research Site, Sherman

Research Site, Bordeaux

Research Site, Bournemouth

Research Site, Leeds

Research Site, Manchester